ArticleACS applied bio materials2021
Antibody-Functionalized Halloysite Nanotubes for Targeting Bacterial Cells.
Article in ACS applied bio materials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Halloysite-Nanotube-Mediated High-Flux γ-AlMembranes · 2025Article
- Chitosan-Clay Mineral Nanocomposites with Antibacterial Activity for Biomedical Application: Advantages and Future Perspectives.International journal of molecular sciences · 2024Review
- Antimicrobial Nanomaterials Based on Halloysite Clay Mineral: Research Advances and Outlook.Antibiotics (Basel, Switzerland) · 2022Review
- Gold Nanorod-Incorporated Halloysite Nanotubes Functionalized with Antibody for Superior Antibacterial Photothermal Treatment.Pharmaceutics · 2022Article
- Nanoclays: Promising Materials for Vaccinology.Vaccines · 2022Review
- Biotransformation of (-)-Isopulegol byPharmaceuticals (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Halloysite nanotubes (HNTs) are naturally occurring tubular clay particles which have emerged in recent years as a promising nanomaterial for numerous applications. Specifically, HNTs' large pore volume and high specific surface area in combination with their biocompatibility make them ideal nanocarriers for bioactive compounds. This research aims to design and synthesize functionalized HNTs, which could selectively bind to target bacterial cells in suspension. Such a system can allow us to treat target cells within a challenging heterogeneous population, such as contaminated ecosystems or gut flora. HNTs functionalization is achieved by immobilizing specific antibodies onto the nanotube surface. The synthetic route is realized by the following subsequent steps: acidic etching of the HNTs, silanization of reactive surface hydroxyls, conjugation of protein A, and oriented immobilization of the antibody. HNT functionalization is studied by a set of analytical techniques including attenuated total reflectance Fourier-transform infrared spectroscopy, zeta potential measurements, thermal gravimetric analysis, scanning and transmission electron microscopy, as well as fluorescence microscopy. The selective binding of the functionalized HNTs to their target bacteria is observed upon incubation with live homogenous and heterogeneous cultures using fluorescence microscopy and high-throughput flow cytometry. Plate count and live/dead staining experiments demonstrate the biocompatibility of the antibody-HNT hybrid with its target bacteria. The suggested HNT-based smart carrier constitutes a generic platform for targeted delivery that could be selectively tailored against any microorganism by facile antibody adjustment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.